Only weeks after debuting generic competition in the US to Boehringer Ingelheim’s Spiriva HandiHaler (tiotropium bromide inhalation powder) 18mcg/capsule, Lupin has struck an alliance with the Mark Cuban Cost Plus Drug Company, which the Indian firm hopes will expand availability for the key chronic obstructive pulmonary disease treatment. As part of the move, Lupin has at the same time penned an agreement with Florida-based non-profit the COPD Foundation.
Lupin And Mark Cuban Shake Hands On Spiriva Alliance In US
Indian Firm Recently Launched First Generic; Aiming For 40%+ Share
Self-labelled ‘disruptor’ Mark Cuban has brought on board yet another high-demand prescription drug, following a recent deal for biosimilar Humira.
